Metabolic reprogramming of the ovarian cancer microenvironment in the development of antiangiogenic resistance
- PMID: 37021977
- PMCID: PMC10326423
- DOI: 10.3724/abbs.2023046
Metabolic reprogramming of the ovarian cancer microenvironment in the development of antiangiogenic resistance
Abstract
Antiangiogenic therapies, such as treatment with bevacizumab, display modest survival benefits in ovarian cancer (OC) patients. After a transient response, the upregulation of compensatory proangiogenic pathways and the adoption of alternative vascularization processes lead to the development of resistance. Considering the high mortality rate of OC, there is an urgent need to uncover the underlying mechanisms of antiangiogenic resistance for the development of novel and effective treatment strategies. Recent investigations have confirmed that metabolic reprogramming in the tumor microenvironment (TME) exerts an essential effect on tumor aggressiveness and angiogenesis. In this review, we provide an overview of the metabolic crosstalk between OC and the TME, highlighting the regulatory mechanisms underlying the development of antiangiogenic resistance. Metabolic interventions may interrupt this complex and dynamic interactive network, providing a promising therapeutic option to improve clinical outcome in OC patients.
Keywords: antiangiogenic therapy; metabolism; ovarian cancer; tumor microenvironment.
Conflict of interest statement
The authors declare that they have no conflict of interest.
Figures


Similar articles
-
Anti-angiogenic therapy in ovarian cancer: current situation & prospects.Indian J Med Res. 2021 May;154(5):680-690. doi: 10.4103/ijmr.IJMR_1160_19. Indian J Med Res. 2021. PMID: 35532586 Free PMC article. Review.
-
New insights into antiangiogenic therapy resistance in cancer: Mechanisms and therapeutic aspects.Drug Resist Updat. 2022 Sep;64:100849. doi: 10.1016/j.drup.2022.100849. Epub 2022 Jun 30. Drug Resist Updat. 2022. PMID: 35842983 Review.
-
Are antiangiogenics a good 'partner' for immunotherapy in ovarian cancer?Angiogenesis. 2020 Nov;23(4):543-557. doi: 10.1007/s10456-020-09734-w. Epub 2020 Jul 20. Angiogenesis. 2020. PMID: 32691290 Free PMC article. Review.
-
State of the art and up-and-coming angiogenesis inhibitors for ovarian cancer.Expert Opin Pharmacother. 2020 Sep;21(13):1579-1590. doi: 10.1080/14656566.2020.1775813. Epub 2020 Jun 17. Expert Opin Pharmacother. 2020. PMID: 32552175 Review.
-
A Quininib Analogue and Cysteinyl Leukotriene Receptor Antagonist Inhibits Vascular Endothelial Growth Factor (VEGF)-independent Angiogenesis and Exerts an Additive Antiangiogenic Response with Bevacizumab.J Biol Chem. 2017 Mar 3;292(9):3552-3567. doi: 10.1074/jbc.M116.747766. Epub 2016 Dec 29. J Biol Chem. 2017. PMID: 28035003 Free PMC article.
Cited by
-
Exploring the underlying biology of cancer and potential therapeutic strategies: a special issue focused on mechanism-based studies.Acta Biochim Biophys Sin (Shanghai). 2023 Jun 19;55(6):891-892. doi: 10.3724/abbs.2023114. Acta Biochim Biophys Sin (Shanghai). 2023. PMID: 37337636 Free PMC article. No abstract available.
-
TCF3 as a multidimensional biomarker: oncogenicity, genomic alterations, and immune landscape in pan-cancer analysis.Acta Biochim Biophys Sin (Shanghai). 2024 Aug 27;57(2):195-208. doi: 10.3724/abbs.2024126. Acta Biochim Biophys Sin (Shanghai). 2024. PMID: 39205642 Free PMC article.
-
Direct antitumor activity of bevacizumab: an overlooked mechanism?Front Pharmacol. 2024 Apr 23;15:1394878. doi: 10.3389/fphar.2024.1394878. eCollection 2024. Front Pharmacol. 2024. PMID: 38716237 Free PMC article. No abstract available.
-
Bevacizumab in ovarian cancer therapy: current advances, clinical challenges, and emerging strategies.Front Bioeng Biotechnol. 2025 May 15;13:1589841. doi: 10.3389/fbioe.2025.1589841. eCollection 2025. Front Bioeng Biotechnol. 2025. PMID: 40474872 Free PMC article. Review.
-
Integrating bulk RNA-seq and scRNA-seq analyses with machine learning to predict platinum response and prognosis in ovarian cancer.Sci Rep. 2025 May 31;15(1):19123. doi: 10.1038/s41598-025-99930-9. Sci Rep. 2025. PMID: 40450069 Free PMC article.
References
-
- Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. . 2022;72:7–33. doi: 10.3322/caac.21708. - DOI - PubMed
-
- Kuroki L, Guntupalli SR. Treatment of epithelial ovarian cancer. BMJ (Clinical research ed) 2020, 371: m3773 - PubMed
-
- Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, Mannel RS, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. . 2011;365:2473–2483. doi: 10.1056/NEJMoa1104390. - DOI - PubMed
-
- Oza AM, Cook AD, Pfisterer J, Embleton A, Ledermann JA, Pujade-Lauraine E, Kristensen G, et al. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. Lancet Oncol. . 2015;16:928–936. doi: 10.1016/S1470-2045(15)00086-8. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical